Latest Research

Tox Free Solutions (TOX) - FY17 Guidance

Tox Free Solutions Logo

TOX’s segment expectations are largely positive aside from the ongoing challenging conditions in the Pilbara. Revised guidance for underlying FY17 EBITDA of $82-83m is slightly below our prior forecast, but importantly, we believe TOX will emerge from the current financial year with a strong, diversified base off which to grow. We are not expecting large acquisitions in the near term and FY18 will provide cleaner, easier to analyse, numbers. Our $2.50 blended valuation and buy call are maintained

To access our review of Tox Free Solutions please log in under the Client Area Log In at the bottom of this page.

Argonaut’s Client Area allows you to view delayed share prices, access Argonaut’s wealth of Research as well as create custom portfolios and set up company watch lists.

If you would like to access our research please contact us to create an account.

Perth:
This email address is being protected from spambots. You need JavaScript enabled to view it.
+61 8 9224 6888

Hong Kong:
This email address is being protected from spambots. You need JavaScript enabled to view it.
+852 3557 4888
 

 



Google+